Definition of disease-free survival: this is my truth–show me yours
Open Access
- 28 September 2005
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 16 (11) , 1719-1721
- https://doi.org/10.1093/annonc/mdi373
Abstract
In the wake of significant advances made in the treatment of advanced colorectal cancer, progress has also been made in the adjuvant treatment of this disease, for example with oxaliplatin having been shown to add benefit to 5-flurouracil (5-FU)-based adjuvant chemotherapy in two major studies [1, 2]. These studies used two different definitions of 3-year disease-free survival (DFS) as the primary end point, and reflect the contemporary interest in different possible definitions of this outcome measure relative to its use as a surrogate for overall survival (OS), the latter traditionally regarded as the ultimate measure of treatment benefit.Keywords
This publication has 20 references indexed in Scilit:
- Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized TrialsJournal of Clinical Oncology, 2005
- A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Results of NSABP Protocol C-07Journal of Clinical Oncology, 2005
- A phase III randomized trial of LV5FU2+CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802)Journal of Clinical Oncology, 2005
- Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3)Journal of Clinical Oncology, 2005
- A phase III trial comparing oral UFT to FULV in stage II and III carcinoma of the colon: Results of NSABP Protocol C-06Journal of Clinical Oncology, 2004
- Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon CancerNew England Journal of Medicine, 2004
- Clinical Trial to Assess the Relative Efficacy of Fluorouracil and Leucovorin, Fluorouracil and Levamisole, and Fluorouracil, Leucovorin, and Levamisole in Patients With Dukes' B and C Carcinoma of the Colon: Results From National Surgical Adjuvant Breast and Bowel Project C-04Journal of Clinical Oncology, 1999
- Adjuvant 5-Fluorouracil and Leucovorin With or Without Interferon Alfa-2a in Colon Carcinoma: National Surgical Adjuvant Breast and Bowel Project Protocol C-05JNCI Journal of the National Cancer Institute, 1998
- The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03.Journal of Clinical Oncology, 1993
- Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02.Journal of Clinical Oncology, 1990